TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00319488
Drug: Inhaled Corticosteroid (Budesonide)
Normalized name: budesonide Inhalation Suspension
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
Study: NCT02298660
Drug: BOTOX
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: BOTOX® Total dose per patient: 200U Number of cycles:1 cycle~200 units of BOTOX® will be injected per procedure. BOTOX® will be diluted in 15mL saline to 20U/mL. BOTOX® injections will be performed with a normal 22 FF rigid cystoscopy or flexible 6Fr injection needle. BOTOX® will be injected into the detrusor muscle at 20 sites (10U per site), sparing the trigone. A local anaesthesia with instillation of 50 ml lidocaine 2% into the bladder will be done prior to the procedure to avoid autonomic dysreflexia.
Study: NCT02121613
Drug: Tamsulosine LP
Normalized name: LP-20
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration - 0.4 mg daily.
Study: NCT00319488
Drug: Leukotriene Receptor Antagonist (Montelukast Sodium)
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
Study: NCT00319488
Drug: Inhaled Albuterol
Normalized name: albuterol Inhalation Solution
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive inhaled albuterol treatments four times a day.
Study: NCT02121613
Drug: Placebo matching Tamsulosine LP
Normalized name: LP-20
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration - daily.
Study: NCT01338298
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole dosing will begin at 5 mg/day once daily and increased to 10mg by mouth once daily at the end of week 2 and then increased to 15 mg/day once daily at the end of week 8 in women who have not yet regained their menstrual period. If a woman gets her menstrual period on the 5 or 10 mg dose she will remain on this dose for the study.
Study: NCT00501904
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00582075
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5
Study: NCT03376295
Drug: LABA and the LAMA tiotropium (LABA-TIO)
Normalized name: formoterol and tiotropium bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combinational drug
Study: NCT03376295
Drug: LABA and an ICS (LABA-ICS)
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: combinational drug
Study: NCT03745885
Drug: Supaglutide injection
Normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered SC in the Supaglutide arms.
Study: NCT00299611
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.
Study: NCT00299611
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.
Study: NCT00123669
Drug: 500 mg of depot hydroxy-progesterone
Normalized name: 17-alpha-hydroxy-progesterone caproate
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An intramuscular injection of 500 mg of depot hydroxy-progesterone 5 to 15 days prior to surgery.
Study: NCT00062803
Drug: Warfarin VKA
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01252225
Drug: 10 % Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose
Study: NCT01252225
Drug: 10 % Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.
Study: NCT00747110
Drug: budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3x 3mg budesonide capsules once daily
Study: NCT00747110
Drug: mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3x 1000mg mesalazine onc daily
Study: NCT00286936
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00285389
Drug: Adriblastin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00285389
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00285389
Drug: Chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00285389
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00285389
Drug: alkeran
Normalized name: Alkeran
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00285389
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,4 mg/day day 1 to day 4
Study: NCT00960570
Drug: Efavirenz 600 mg
Normalized name: efavirenz 600 MG
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz 600 mg administered as a single oral dose on the morning of Day 1.
Study: NCT00960570
Drug: Efavirenz 600 mg
Normalized name: efavirenz 600 MG
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
Study: NCT00960570
Drug: Fenofibric Acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
Study: NCT01252732
Drug: Single-Dose IV Oritavancin Diphosphate
Normalized name: Oritavancin Diphosphate
DrugBank: Oritavancin (DB04911)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
Study: NCT01252732
Drug: IV Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
Study: NCT01071018
Drug: MK2206 every other day
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles.
Study: NCT02374008
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00622752
Drug: EVT 302, 10 mg
DrugBank: EVT 302 (DB06057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X EVT 302, 5 mg tablets
Study: NCT00622752
Drug: Nicotine replacement therapy (NRT)
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NRT patch containing 21 mg of nicotine
Study: NCT03056456
Drug: Insulin Lispro (Humalog)
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT00142961
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atomoxetine
Study: NCT00027989
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03219970
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80mg oral daily
Study: NCT00457106
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00457106
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00975897
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00975897
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00262483
Drug: VX-950
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02102204
Drug: Etelcalcetide
Normalized name: Etelcalcetide
DrugBank: Etelcalcetide (DB12865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etelcalcetide was supplied as a sterile, preservative-free, ready-to-administer aqueous solution.
Study: NCT01027806
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 pill per day for 4 months
Study: NCT00609531
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill, 5-20mg once a day for twelve weeks
Study: NCT00262483
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00262483
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02632448
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 to 600 milligrams per square meter of body surface area (mg/m2)
Study: NCT02611596
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of the assigned medication
Study: NCT01886599
Drug: Asunaprevir
Normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT00788177
Drug: Pegaptanib (Macugen®)
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)
Study: NCT01014351
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel, 175mg/m2 by IV infusion over 1-3 hours on day 1 of every 21 day cycle
Study: NCT01014351
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin, AUC 6 given by IV infusion over 20-30 minutes on day 1 of every 21 day cycle
Study: NCT01014351
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus, 5 mg by mouth (PO) once a day, continuous dosing every 21-day cycle
Study: NCT03370172
Drug: BAX 888
Normalized name: BAX 888
DrugBank: TAK-754 (DB17850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1, 2, 3 on Day 0.
Study: NCT02223702
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg, 3 times per day for 7 days
Study: NCT02223702
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg, 3 times per day, for 7 days
Study: NCT02223702
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg, once in a day for 7 days.
Study: NCT02537158
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
Study: NCT02405442
Drug: Andecaliximab
Normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andecaliximab administered via subcutaneous (SC) injection
Study: NCT03241030
Drug: Sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will receive 20mg/kg/dose up to 1 gram.
Study: NCT00874939
Drug: MK-0249 7.5 mg
DrugBank: MK-0249 (DB11910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
Study: NCT00874939
Drug: MK-0249 25 mg
Normalized name: vitamin MK 7
DrugBank: MK-0249 (DB11910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
Study: NCT00874939
Drug: Donepezil 5mg
Normalized name: DONEPEZIL 5MG RAPID DISINTEGR TAB
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 5 mg tablet, single oral dose during each crossover period
Study: NCT00874939
Drug: Placebo to MK-0249
Normalized name: MK-0249
DrugBank: MK-0249 (DB11910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five tablets, single oral dose during each crossover period
Study: NCT00874939
Drug: Placebo to Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One over-encapsulated capsule, single oral dose during each crossover period
Study: NCT00444678
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 500 mg/m2, IV every two weeks
Study: NCT00444678
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m2, IV, q 2 weeks
Study: NCT00504946
Drug: montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children \> 14 years old received 10mg oral tablet once daily at bedtime
Study: NCT04342130
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg oral tablet
Study: NCT00756912
Drug: E5564
Normalized name: Eritoran
DrugBank: Eritoran (DB04933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
Study: NCT01816334
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01816334
Drug: Sodium Chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004199
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004199
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004199
Drug: prinomastat
Normalized name: Prinomastat
DrugBank: Prinomastat (DB05100)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03130556
Drug: Glasdegib
Normalized name: Glasdegib
DrugBank: Glasdegib (DB11978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.
Study: NCT03130556
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A subset of subjects will receive repeated daily dosing of 40 mg rabeprazole for 7 days with 100 mg single dose of ICH glasdegib being administered on Day 7.
Study: NCT00832286
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed medication, dose: 500 mg every 12 hours for 3 days.
Study: NCT02766556
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ISB with ropivacaine with dexmedetomidine or normal saline
Study: NCT02766556
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ISB with ropivacaine with dexmedetomidine or normal saline
Study: NCT04664764
Drug: Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Basal insulin comparison
Study: NCT03468426
Drug: BI 836880
Normalized name: BI-836880
DrugBank: BI-836880 (DB17484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-venous infusion
Study: NCT03468426
Drug: ezabenlimab
Normalized name: Ezabenlimab
DrugBank: Ezabenlimab (DB17483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-venous infusion
Study: NCT00357734
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
Study: NCT00118209
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV or CIVI
Study: NCT04664764
Drug: Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Basal insulin comparison
Study: NCT00118209
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00118209
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CIVI
Study: NCT00118209
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV
Study: NCT00118209
Drug: pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV
Study: NCT03843775
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID
Study: NCT03843775
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: encorafenib 450 mg oral QD
Study: NCT03452722
Drug: intraventricual recombinant tissue plasminogen activator application
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Plasminogen (DB16701)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01049009
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug.
Study: NCT01049009
Drug: Metoprolol XL
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug.
Study: NCT00564057
Drug: candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet 8-16 mg once daily, one year
Study: NCT00564057
Drug: lercanidipine
Normalized name: Lercanidipine
DrugBank: Lercanidipine (DB00528)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets 10-20 mg once daily, one year
Study: NCT00859456
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Taken daily PO for a 42 day cycle. This cycle is repeated at least twice.~A small molecule, multi-targeted receptor tyrosine kinase inhibitor that selectively targets and intracellularly blocks the signaling pathways of receptor tyrosine kinase (RTKs).
Study: NCT04518189
Drug: lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine patch applied 3 hours before the procedure
Study: NCT04518189
Drug: Sham patch
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham patch applied 3 hours before the procedure
Study: NCT02180659
Drug: sublingual buprenorphine tablets
Normalized name: buprenorphine Sublingual Tablet
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02180659
Drug: Buprenorphine implant
Normalized name: buprenorphine Drug Implant
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03000075
Drug: risankizumab
Normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
Study: NCT03000075
Drug: placebo for risankizumab
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
Study: NCT00640224
Drug: rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg daily for 6 months
Study: NCT02535156
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 mg Risperidone
Study: NCT01613846
Drug: Sorafenib+Pazopanib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib (first-line) followed by Pazopanib (second-line)
Study: NCT01613846
Drug: Pazopanib+Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pazopanib (first-line) followed by Sorafenib (second-line)
Study: NCT01667419
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.
Study: NCT01814709
Drug: GDC-0032
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral doses of GDC-0032
Study: NCT01814709
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral doses of Itraconazole